Teladoc Health (NYSE:TDOC) Given New $10.00 Price Target at Royal Bank of Canada

Teladoc Health (NYSE:TDOC) had its target price increased by stock analysts at Royal Bank of Canada from $9.00 to $10.00 in a report released on Wednesday, Benzinga reports. The brokerage presently has an “outperform” rating on the health services provider’s stock. Royal Bank of Canada’s price objective would suggest a potential upside of 11.48% from the stock’s current price.

Other equities analysts also recently issued reports about the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 target price on shares of Teladoc Health in a research report on Tuesday, August 20th. TD Cowen decreased their target price on shares of Teladoc Health from $15.00 to $9.00 and set a “hold” rating on the stock in a research report on Thursday, August 1st. Truist Financial dropped their price target on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating for the company in a research report on Friday, August 2nd. Barclays decreased their price target on shares of Teladoc Health from $20.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. Finally, Needham & Company LLC restated a “hold” rating on shares of Teladoc Health in a report on Thursday, August 1st. Fifteen equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Teladoc Health currently has a consensus rating of “Hold” and an average target price of $11.81.

Teladoc Health Trading Up 3.0 %

NYSE:TDOC traded up $0.26 on Wednesday, reaching $8.97. The stock had a trading volume of 1,095,092 shares, compared to its average volume of 5,468,732. The firm’s fifty day moving average is $7.86 and its two-hundred day moving average is $10.31. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.66 and a quick ratio of 1.62. The company has a market cap of $1.54 billion, a price-to-earnings ratio of -6.36 and a beta of 0.91. Teladoc Health has a 12-month low of $6.76 and a 12-month high of $22.54.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, July 31st. The health services provider reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.08. The firm had revenue of $642.44 million during the quarter, compared to analysts’ expectations of $649.34 million. Teladoc Health had a negative net margin of 38.54% and a negative return on equity of 10.25%. Equities analysts expect that Teladoc Health will post -1.18 EPS for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In related news, insider Vidya Raman-Tangella sold 3,857 shares of Teladoc Health stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $31,395.98. Following the completion of the transaction, the insider now directly owns 33,667 shares in the company, valued at approximately $274,049.38. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Vidya Raman-Tangella sold 3,857 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total transaction of $31,395.98. Following the sale, the insider now directly owns 33,667 shares of the company’s stock, valued at approximately $274,049.38. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Laizer Kornwasser sold 10,879 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $88,555.06. Following the transaction, the chief executive officer now owns 99,929 shares in the company, valued at $813,422.06. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 57,377 shares of company stock worth $438,054 in the last ninety days. 0.95% of the stock is owned by insiders.

Institutional Investors Weigh In On Teladoc Health

A number of institutional investors have recently modified their holdings of TDOC. Wedmont Private Capital acquired a new position in Teladoc Health during the 3rd quarter valued at approximately $120,000. CWM LLC increased its position in Teladoc Health by 219.1% in the third quarter. CWM LLC now owns 13,557 shares of the health services provider’s stock worth $124,000 after buying an additional 9,309 shares during the period. SG Americas Securities LLC lifted its stake in Teladoc Health by 41.2% in the third quarter. SG Americas Securities LLC now owns 76,891 shares of the health services provider’s stock valued at $706,000 after buying an additional 22,424 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Teladoc Health by 194.2% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 6,891 shares of the health services provider’s stock valued at $67,000 after acquiring an additional 4,549 shares during the period. Finally, Granite Bay Wealth Management LLC bought a new position in shares of Teladoc Health during the second quarter worth about $1,111,000. Institutional investors own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.